Levi & Korsinsky LLP announces that it has commenced an investigation of HeartWare International Inc. (“HeartWare” or the “Company”) (NasdaqGS:HTWR) concerning possible violations of federal securities laws by certain officers and directors.

On October 13, 2015, HeartWare announced that the company may not reinitiate enrollment in its MVAD heart pump clinical trials in November 2015, as previously announced. On the announcement of this news, the share price of HeartWare stock has plunged as much as $7.63 per share, or more than 17%, during intraday trading from its October 12, 2015 closing price of $44.03 to trade under $37.00 per share on October 13, 2015. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/heartware-international-htwr

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.